Abstract
In order to determine if age and comorbidity influence the tolerability of the cytoprotective agent amifostine, we compared side effects related to amifostine in patients > or = 70 years (group I) with patients < 70 years (group II). We evaluated 268 consecutive administrations of amifostine (119 in group I and 149 in group II, respectively), given i.v. at a dose of 740 mg/m(2) just before platinum-, taxol- or cyclophosphamide-based chemotherapy. Transient hypotension was the most common side effect occurring in association with amifostine. Decreases in systolic blood pressure > 20 mmHg were of similar frequency in both groups (27.1 versus 28.8% of amifostine infusions in group I and II, respectively). Hypotension did not result in medical sequelae in any of the patients. The amifostine infusion was interrupted 16 times in group I and 8 times in group II, respectively, mainly due to hypotension, but could be restarted after a few minutes in all patients except for three cases in group I. Patients in group II more often suffered from nausea/vomiting than in group II (20.8 versus 10.0% in group I). Other subjective symptoms (e.g. warmed, flushed sensation, sneezing, metallic taste, mouth dryness, dizziness and sleepiness) and hyp...Continue Reading
References
Nov 10, 1983·The New England Journal of Medicine·D GloverS Goldfarb
Aug 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S WadlerC Runowicz
Dec 1, 1995·Drugs·C M Spencer, K L Goa
Jun 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J H SchillerW Berry
Jul 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G KempJ Glick
Jan 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R M Bukowski
Oct 8, 1997·Cancer·R E Vestal
Mar 13, 1999·Seminars in Oncology Nursing·K G O'Connor
Citations
Apr 4, 2008·Cell Biology and Toxicology·Alan R ParrishBruce D Hammock
Jan 22, 2004·Critical Reviews in Oncology/hematology·Sandro Pignata, Jan B Vermorken
Sep 18, 2012·Journal of Radiation Research·Chengjie ChenChangquan Ling
May 2, 2002·Anti-cancer Drugs·Ernst Späth-SchwalbeKurt Possinger
Mar 16, 2005·BMJ : British Medical Journal·Bo AbrahamsenKim Brixen
Oct 25, 2013·International Journal of Biological Sciences·Liren QianJianming Cai
Jul 19, 2014·Journal of Radiation Research·Sadahiro WatanabeYasuhiro Kanatani
Nov 11, 2003·Clinical Pharmacokinetics·Hans WildiersAllan T van Oosterom
Aug 12, 2009·Medical Hypotheses·Cong LiuJianming Cai
Jan 1, 2004·Current Therapeutic Research, Clinical and Experimental·Sabri BarutcaZahit Bolaman
Feb 20, 2010·Free Radical Research·Liren QianJianming Cai
Jun 5, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Tyler W LeBaronJan Slezak
Sep 1, 2015·Head & Neck·Clemens HeiserAndreas Knopf
Jun 4, 2020·Therapeutic Advances in Medical Oncology·ZhiYu DuanXiangMei Chen